Patent · US Active

2-(morpholin-4-yl)-1,7-naphthyridines

US11529356B2 · kind B2 · utility

0Cited by

6References

20Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Lars Wortmann · Berlin, DE
Ulrich Lücking · Berlin, DE
Julien LEFRANC · Berlin, DE
Hans Briem · Bremen, DE
Marcus Koppitz · Berlin, DE
Knut Eis · Berlin, DE
Franz VON NUSSBAUM · Val-de-Reuil, FR
Benjamin Bader · Berlin, DE
Antje Margret Wengner · Berlin, DE
Gerhard Siemeister · Berlin, DE
Wilhelm Bone · Berlin, DE
Philip Lienau · Berlin, DE
Joanna Grudzinska-Goebel · Berlin, DE
Dieter MOOSMAYER · Berlin, DE
Uwe Eberspächer · Berlin, DE
Hans SCHICK · Berlin, DE

Key dates

Filing date	Aug 21, 2020
Grant date	Dec 20, 2022
Priority date	—
Expiry date	Nov 16, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07F9/6561
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.